 |
 |
 |
 |
|
 |
|
Portrait(R)
Plasma Skin Regeneration
|
|
 |
|
 |
|
 |
|
 |
|
|
Main Category:
Dermatology News
Article Date: 20 Sep 2006 - 0:00am (PDT)
|
email this article |
printer friendly |
view or write opinions |
Rhytec, Inc. announced today that the Food and Drug
Administration cleared Portrait(R) Plasma Skin
Regeneration (Portrait(R) PSR3) system, for use in
treating non-facial rhytides (wrinkles). Portrait(R)
PSR3 was cleared in 2005 for the treatment of wrinkles
of the face and in 2003 for the treatment of facial and
non-facial areas for superficial skin lesions, actinic
keratosis, seborrhoeic keratosis and viral papillomata.
This new FDA clearance, coupled with the previous
clearances, makes Portrait(R) the only plasma skin
regeneration technology available for patients seeking
cosmetic improvement for individual or simultaneous
treatment of wrinkles, benign skin lesions and actinic
(sun) damage of the whole body.
Mark Goble, MD, Chief Executive Officer and founder of
Rhytec, Inc. commented, "Our Portrait Plasma Skin
Regeneration system is a uniquely versatile technology
that can be optimized to meet patient expectations in
the treatment of a variety of cosmetic indications. The
broadening of our FDA clearance to encompass treatment
of non-facial areas of the body represents an important
step in realizing the potential of our technology and
creating value for our customers and clinical results
for patients."
About Portrait(R)
Portrait(R) delivers nitrogen plasma (a highly energized
gas) energy, which works both at and below the surface
of the skin to modify the skin's architecture and
generate new collagen. The skin's outer layers remain
intact and act as a protective cover until new skin
regenerates. Once this happens, the old skin peels away
taking with it all the signs of years of exposure to the
sun, including brown sun spots and actinic keratoses
(rough-textured patches or lesions that form on the
outermost layer of the skin), fine lines and deep
wrinkles. Additionally Portrait(R) has profound
sustainable cosmetic effects on skin tone, texture and
laxity. All of these conditions are treated
simultaneously -- a unique and significant advantage
that distinguishes Portrait(R) from other cosmetic skin
treatments. There is no evidence of scarring or
hypopigmentation in clinical studies to date.
About Rhytec
Rhytec develops innovative technologies based on sound
scientific and clinical research for the dermatological,
plastic and cosmetic surgery markets. Plasma energy
stimulates a true skin regenerative process that is
supported by 30 completed and ongoing clinical trials.
Founded in 2004, Rhytec works with leading plastic
surgeons, dermatologists and cosmetic physicians to
develop new technologies that enhance the skin's
appearance and function in order to improve the quality
of life for patients seeking treatment. Rhytec, Inc. is
privately held, based in Waltham, MA (US) and is a
subsidiary of Rhytec, Ltd. in Berkshire (UK).
Rhytec
http://www.rhytec.com
|
|
|
|
|
|
|
|
|
|
|
copyright © 2010, NursingAgencyKit.com powered by Cyberlearningsystems.com™ |
|
|